BMO Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $70 and keeps an Outperform rating on the shares. The company’s AATD discontinuation is the right decision and ...
Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target ...
4h
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO ...
Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...
The largest of the wildfires ravaging the area shifted direction, triggering more evacuation orders and posing a new challenge to exhausted firefighters.
Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback